CASE STUDY — ケーススタディ
ク リ ニ カ ル リ サ ー チ プ ラ ッ ト フ ォ ー ム
I led design for an AI-powered clinical research platform, from the brand identity to a two-sided enterprise product that connects research sites with CROs.
ROLE
Design Lead, team of 3
TIMELINE
1–2 Years
STATUS
Pilot / Early Customers
COMPLIANCE
HIPAA + 21 CFR Part 11
問題 THE PROBLEM
Clinical trial recruitment keeps failing the people it’s meant to help.
MISS RATE
80%
of clinical trials miss their initial enrollment timelines, costing pharma millions a day in opportunity cost alone
TERMINATION CAUSE
57%
of clinical trial terminations are due to enrollment difficulties. The research just stops, and the funding goes down the drain
Those numbers mean cures arrive late, patients lose access to treatments that could save their lives, and drug prices go up to pay for slow research. The clinical staff doing the work burn out, too.
リサーチ RESEARCH & MANDATE
I was brought in to understand a space the previous design lead couldn’t.
Clinical research has its own language, and its workflows are the way they are for good reasons. Start designing before you understand them and you’ll break something. So I interviewed clinical researchers, PIs, site coordinators, and monitors at all kinds of institutions. I had to account for blinding protocols, randomization structures, and cohort configurations, plus how all of it changes depending on whether the sponsor is a major CRO like IQVIA or a more in-house operation.
The hard part was working out which edge cases were common enough to design for and which were one site’s customization. Get that wrong and you build a tool that works for one workflow and fails everyone else.
I’m fluent in it now, but getting there took a lot of interviews across the US, with researchers at different kinds of institutions, major CROs, and boutique sponsors. I didn’t feel ready to design until I had that wide a picture.
プロダクト THE PLATFORM
One platform for everyone involved in a trial.
Right now, sites patch this together with two or three tools that were never built to work with each other. Centrova puts all of it in one place, which is the main thing that sets it apart.
SMARTMATCH
A bidirectional matching engine. It finds the right patients for a trial, or the right trials for a patient, using a proprietary tagging database built from clinicaltrials.gov and patient records.
AI SCREENING
Evaluates patients against trials in bulk. Every AI recommendation shows the exact line in the patient file it’s based on, and the researcher makes the final call.
TRIAL MANAGER
Browse, configure, and manage every trial, with role-based access, double-blind support, enrollment tracking, and direct criteria editing for when clinicaltrials.gov gets it wrong.
DATA HUB
Shared file storage for visit data, trial documentation, deviation logs, and direct data entry, with one-click export to sponsors.
CLINICAL TEAMS
Trial channels, direct messages, and monitor-to-site lines for sending queries and receiving site reports. Blinded and unblinded chats stay separate to protect double-blind studies.
MONITOR PORTAL
A section where CRO monitors review evaluations, finalize enrollment, and request compliance documents without scheduling a remote visit or sending a single email.
デザイン KEY DESIGN DECISIONS
The hardest problems were about structure.
01
Adding monitors to the platform
This was probably the biggest product call I made, and it came straight out of research. Monitors and sites work on the same trials, but the way their workflows are set up, they’re constantly jumping through hoops to share information: email chains, phone calls, remote visits. For how often they need to talk, it’s wildly inefficient.
The interviews showed me that Centrova sits in an unusual spot. We hold patient data relevant to screening, but we’re not an EHR. That means we can give monitors the access they need without the tight restrictions that slow everything down, and still keep it HIPAA-compliant and properly deidentified.
I took this to the CEO and COO with the interview data to back it up. It was outside the original scope, but they got on board, and in the pilot it turned out to be one of the features monitors liked most.
02
Redesigning the screening flow
Putting a pre-match score right in patient selection means the screen is never blank. The most likely candidates stand out before the researcher has done anything, and I think it’s one of the strongest features in the platform.
03
AI that shows its work
In a regulated clinical setting, you can’t let an algorithm make enrollment decisions and expect people to trust it. So the AI does the heavy lifting, screening every selected patient against every trial criterion at once, and links each decision to the exact line in the patient’s file it relied on. Researchers then make the final call on each criterion themselves. That’s for compliance as much as trust: clinical responsibility stays with qualified staff, and the double-check is required by design.
04
A visual identity for researchers
Before touching anything, we held a full brand meeting with the design team. We landed on a look that feels like research more than like a hospital, because researchers don’t see themselves as hospital administrators. We also didn’t want to look too tech-forward. In high-stakes settings, being flashy about AI makes people trust you less. So we went with large typography, a top nav, and content front and center, and stayed away from anything that looks like it came out of a Shadcn template.
成果 OUTCOMES
Screening went from about 90 minutes to 5–10.
~90 minutes
5–10 minutes
Email, phone, remote visits
Unified in-platform
2–3 disconnected tools
1 integrated platform
Manual, inconsistent
Auto-generated PDF
In pilot feedback, monitors said having communication, screening history, and files in one place was much simpler than their current multi-tool setup. PIs liked the role-based access and being able to see how the AI reached its screening decisions.
Going from 90 minutes to 5–10 is roughly a tenfold change. For the first time, sites can screen large patient populations in bulk without hiring staff to match.
振り返り REFLECTION
The research did more for this product than any screen I designed.
The interviews are why I pushed to include monitors in the platform. That changed the product’s scope and what it offers, and it’s why Centrova can go after the fragmented communication that slows clinical research down. The original brief hadn’t accounted for that problem, and I only found it in the interviews.
The screening redesign taught me something too. The wizard looked simple on paper and fell apart in practice. The Screening Center looks more complicated, but it matches how researchers really work, so it ends up feeling simpler to use.
Centrova is still in pilot. We’re building one compliant platform, with AI built in, that connects everyone involved in a clinical trial. If we get that right, I think it can shorten the time between a medical discovery and patients getting access to it.
